12-04 :: April/May 2012
nanotimes
Companies Facts
investor. Under the terms of the agreement, AMSC raised approximately $25 million in gross proceeds through the sale of convertible notes and warrants. The proceeds will be used for working capital and general corporate purposes.
A
“This financing provides an added backstop for our business as we pursue our growth and diversification strategy,” said AMSC President and Chief Executive Officer Daniel P. McGahn. “We have been meeting our business objectives and significantly reducing our cash usage. With a bolstered balance sheet, we are focusing our efforts on enabling customer success and achieving sustainable profitability.”
http://www.amsc.com
bution partner for Korea. Digichem, a management innovation enterprise, specializes in exporting che- mical ingredients and intermediates for markets that include paint and coatings, adhesives, automotive, electronics, pharmaceutical, printing and packaging.
A
http://www.angstronmaterials.com
electronics for wireless communications from an exi- sting customer, a global mobile solutions provider.
A
http://www.apitechnologies.com
PI Technologies Corp. (NASDAQ: ATNY) has received a new $1.1m order to provide critical
a
ngstron Materials Inc., has named Digichem Corporation, Anyang City, Korea, its distri-
MSC (NYSE: AMSC) has entered into a securities purchase agreement with an institutional
fiscal 2012 second quarter ended March 31, 2012. In fiscal 2012 second quarter Arrowhead acquired Alvos Therapeutics, Inc. (formerly known as Mer- cator Therapeutics, Inc.), a pioneer in targeting for tumors and tumor vasculature in humans, including a large proprietary library of human-derived targeting peptides, and received FDA clearance to initiate an Adipotide Phase I clinical trial. Moreover, the Com- pany entered into a strategic alliance and master ser- vices agreement for RNAi therapeutics with Axolabs, a German company in the field of oligonucleotide therapeutics.
A
For the quarter ended March 31, 2012, Arrowhead reported revenues of $31,250. There was no revenue in the comparable prior period. Total operating ex- penses for the quarter ended March 31, 2012 were $4.9 million, compared to $1.8 million during the quarter ended March 31, 2011.
Net loss attributable to Arrowhead for the quarter ended March 31, 2012 was $5.3 million, or $0.50 per share based on 10,663,869 weighted average shares outstanding. This compares with a net loss at- tributable to Arrowhead of $2.9 million, or $0.37 per share based on 7,891,395 weighted average shares outstanding, for the quarter ended March 31, 2011.
http://www.arrowheadresearch.com
ustriamicrosystems announced an extension of its 0.35µm High-Voltage CMOS fabrication service, offering Electrostatic Discharge (ESD) protection
rrowhead Research Corporation (NASDAQ: ARWR) announced financial results for its
15
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85